New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.
|Videos|December 13, 2017
Dr. Landi on the Association Between Genetic Variance and Melanoma Risk
Author(s)Maria Teresa Landi, MD, PhD
Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the association between genetic variance and melanoma risk.
Advertisement
Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the association between genetic variance and melanoma risk.
In a large, global, meta-analysis of Caucasian patients, the association between genetic variance and risk of melanoma was evaluated.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
Advertisement
Advertisement
Trending on OncLive
1
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
2
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
3
Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma
4
Refined ADC Development Helps Weigh Biomarker-Based Decisions and Treatment Sequencing in Gynecologic Cancers
5